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Summary  
Personalized medicines require understanding the molecular causes of disease. In 
this issue of Immunity, Gruber et al. identify mosaic expression of a gain-of-function 
JAK1 genetic mutant that drives multi-organ immune dysregulation via kinase 
dependent and independent mechanisms. The work 
highlights how biochemistry  can inform therapies to resolve  immune disorders   
Main Text 
The development of effective treatments for many autoimmune diseases is frequently 
hindered by a lack of understanding of the molecular processes and primary cellular 
perturbations that cause the immune dysregulation. However, the advent of next 
generation DNA sequencing has opened-up the capacity to diagnose the genetic 
causes of rare complex immune disorders which then allows the design of 
personalized and effective clinical management strategies (Lee et al., 2014). However, 
one challenge for understanding how mutations in signaling molecules can drive 
immune dysfunction is that immune cell populations are highly heterogeneous and 
need to be analysed at the level of rare populations or at the single-cell level to 
determine the molecular processes that drive immune phenotypes. In this issue of 
Immunity, Gruber et al. (2020) present strategies that uncovered the molecular basis 
of an undiagnosed complex primary autoinflammatory and atopic syndrome in a 
patient, when standard genetic analysis pipelines failed to find evidence for causal 
germline mutations.  
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The authors hypothesized that the physical asymmetry of disease symptoms in the 
patient reflected that the underlying cause was a de novo mosaic mutation of a key 
molecule for immune cell function (Figure 1). They then applied lower-frequency reads 
from whole-exome-sequencing analysis of the peripheral blood cells of the patient to 
identify DNA mutations that may be present in only a subpopulation of immune cells. 
This DNA sequencing work identified a new variant of the tyrosine kinase, JAK1 
(JAK1c2108GT>T) as a potential disease-causing molecule. However, once identified, 
it was the clever and combined use of in vitro biochemical analyses of the mutant JAK1 
protein and quantitative, single-cell analyses of the patient's immune cells that then 
provided the key insights necessary to understand how cells with the JAK1c2108GT>T 
variant caused immune dysfunction. Importantly, these insights proved crucial for the 
successful selection of a drug to resolve the clinical disease caused by the JAK1 
mutation.  
JAK1 was first identified in an unbiased discovery program that exploited the existence 
of highly conserved sequence elements within the catalytic domains of tyrosine 
kinases to generate degenerate oligonucleotide primers that would identify novel 
kinases (Wilks et al., 1991). We now know that there are four JAK kinases (JAK1, 
JAK2, JAK3 and TYK2), and within cells, the major substrate for JAKs are the STAT 
family transcription factors, of which there are seven (STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B, STAT6) (O’Shea et al., 2015). JAK1 is expressed ubiquitously, and 
is activated by a broad range of cytokine families including common gamma chain 
cytokines (γc), gp130 chain cytokines, interferons and IL-10-family cytokines (O’Shea 
et al., 2015; Schwartz et al., 2017). The STAT-mediated transcriptional programmes 
coupled to JAK1 are highly diverse, as a consequence of the formation of specific 
combinations JAK partners and STATs that associate with distinct cytokine receptors. 
The ability to understand the molecular implications of JAK1 mutations for immune 
cells stems from the pioneering work of scientists in the early 1990s who characterised 
a series of human fibrosarcoma cell lines with chemically induced mutations that 
blocked IFN-α/β and IFN-γ signaling (Müller et al., 1993). One of these was the JAK1-
null UC4 cell line which is completely defective in interferon responses, despite 
expression of TYK2, which partners with JAK1 to mediate IFN-α/β signaling, and 
JAK2, which couples with JAK1 to induce signaling by the IFN-γ receptor. Critically, 
re-expression of JAK1 in the UC4 cell line can restore IFN-α/β and IFN-γ signal 
transduction pathways (Müller et al., 1993). The UC4 cell line is thus an established 
model system for analysis of JAK1 function, and, importantly allows rapid assessment 
of the impact of JAK1 mutations on the activity of TYK2 and JAK2.  
Gruber et al. exploited the U4C system to compare the signaling responses induced 
by either WT JAK1 or the JAK1c2108GT>T variant. The intriguing findings from the 
reconstitution study were JAK1c2108GT>T variant produced a gain of function JAK1 
protein. The JAK1c2108GT>T variant but not WT JAK1, thus stimulated cytokine 
independent phosphorylation of STAT proteins and STAT-induced transcription 
(Figure 1). Moreover, cells expressing the JAK1c2108GT>T variant were 
hyperresponsive to IFN-α, IFN-γ and IL-6 stimulation and showed increased 
phosphorylation of other JAK kinases, JAK2, JAK3 and TYK2 (Figure 1).  The increase 
in basal and stimulated STAT phosphorylation induced by the JAK1 mutant was 
confirmed by the authors in an elegant approach that took advantage of the mosaicism 
of JAK1c2108GT>T variant expression in B-cells to derive clonal immortalized B cell 
lines either expressing WT or mutant JAK1.  
However, it was the in vitro re-constitution experiments that allowed the authors to 
uncover that the JAK1c2108GT>T variant produced a gain of function JAK1 mutant 
that could transactivate partnering JAK kinases, JAK2, JAK3 and TYK 2 independently 
of its catalytic domain. In this respect, the JAK1c2108GT>T variant produces a  protein 
with an S703I mutation within a highly conserved region of the pseudokinase domain 
of JAK1. These JAK pseudokinase domains are thought to keep JAK monomers 
catalytically inert while they are associated with cytokine receptors in the absence of 
ligands (Babon et al., 2014). However, it is unclear whether the pseudokinase-
mediated inhibition occurs through an intramolecular interaction between the kinase 
and pseudokinase within the same protein (cis regulation), or intermolecular between 
two JAK kinases associated with different receptor chains (trans regulation) (Babon et 
al., 2014). Hence, a critical observation by Gruber et al. was that many of the gain-of-
function changes induced by JAK1 S703I were not dependent on JAK1 S7031 
catalytic activity (Figure 1), nor were they completely blocked by selective inhibitors of 
JAK1 enzymatic activity. Rather, pan-JAK inhibitors, which simultaneously target the 
partnering JAKs trans-activated by the JAK1 mutant, were more effective at blocking 
signaling changes induced by JAK1 S703I in cells. Accordingly, Tofacitinib, which was 
developed to target JAK3 but which does have activity against JAK1 and JAK2, has 
proved to be a drug which could effectively treat the clinical disease in the patient with 
the JAK1c2108GT>T variant. These data are, thus, consistent with a model whereby 
the JAK1 S703I mutation in allows the JAK1 pseudokinase domain to regulate JAK 
partners in trans. The salient point is that the reconstitution experiments allowed rapid 
identification of the best drugs to block the functional activity of the JAK1 variant; this 
information was then translated into a treatment that lead to rapid resolution of clinical 
disease in the patient.  
From a translational perspective, the present study illustrates the importance of fully 
understanding the biochemical consequences of kinase mutations for trans-regulation 
of other kinases and other signaling pathways as a basis for choosing effective drugs 
for precision medicine. In this respect, it is perhaps important to consider that JAKs do 
not just phosphorylate STATs but trigger serine and threonine kinase cascades to 
promote phosphorylation of regulators of mRNA translation, chromatin, GTPases, 
vesicle trafficking, and the actin and microtubule cytoskeleton (Ross et al., 2016). 
Moreover, JAKs do not signal in isolation but frequently operate alongside signaling 
pathways mediated by other protein kinases (Ross et al., 2016). Hence, for a patient 
with mosaicism of the JAK1c2108GT>T variant, the observed immune dysregulation 
may be determined by a multitude of factors. JAK1 is expressed ubiquitously, but for 
an individual cell, the ultimate outcome of expressing the JAK1 S7031 variant will be 
determined by the relative abundance of the other JAK and STAT family members in 
that cell. Indeed, the Gruber et al. (2020) study provides clear glimpses of the divergent 
outcome of JAK1 S730I expression for different cytokines and for different cells. For 
example, IL-2 and IL-4 both signal via JAK1 and JAK3 but expression of JAK1 S730I 
caused hyperphosphorylation of STAT5 in response to IL-2 but there was no 
hyperphosphorylation of STAT6 associated with IL-4 stimulation. However, it was 
observed that IL-2 and IL-4 induced phosphorylation of STAT1 occurred in patient and 
not control cells, indicating to the authors that the JAK1 S703I mutant could activate 
non-canonical JAK signaling pathways. One caveat to these observations is that while 
JAK mediated tyrosine phosphorylation is a key driver of STAT mediated 
transactivation, STAT activation may involve additional STAT phosphorylation on 
serine residues (Stark and Darnell, 2012), and there is not a full understanding of how 
STAT serine phosphorylation pathways are co-ordinated. Additionally, the control of 
cell metabolism and protein synthesis is often rate limiting for execution of a cells 
transcriptional program (Wolf et al., 2020) and one question not addressed by Gruber 
et al. is whether expression of the JAK1 S703I variant had any cytokine dependent or 
independent effects on leukocyte metabolism. In particular, there was no assessment 
of the ability of the JAK1 S703I variant to drive protein synthesis. It, thus, remains to 
be determined whether the transcriptional changes initiated by the JAK1 S703I variant 
are alone sufficient to change cell phenotypes. 
In summary, the present study demonstrates how an in-depth characterisation of a 
variant of JAK1 in multiple different immune cells can be used to inform clinical 
treatment. The study discovered a gain-of-function mutation in JAK1 that potentiated 
JAK-dependent signaling pathways, independently of its catalytic activity. The salient 
point is that, it was necessary to block this aberrant signaling to fully reverse the impact 
of the JAK1 mutation on cell phenotype. Together, this highlights the importance of 
molecular immunology, and basic discovery biochemistry for optimised treatments of 
immune disorders.  
Figure legend 
Figure 1: Expression and function of JAK1 S703I 
JAK1 S703I resulted from a variant, JAK1 c2108GT>T allele that arose as a de novo 
mosaic mutation within the first 12 divisions between fertilization and gastrulation. 
Consequently, the patient had cells that were either homozygous for WT JAK1 or 
heterozygous for S703I JAK1. Adding a further layer of complexity, expression of JAK1 
in cells is monoallelic. Hence not all cells heterozygous for S703I JAK1 allele express 
the JAK1 S703I protein. The S703I mutation occurred within a highly conserved region 
of the pseudokinase domain of JAK1. This resulted in a gain-of-function in JAK1 
signaling. JAK1 S703I expression increased the autophosphoylation of JAK1 (yellow 
circles), and the phosphorylation of other JAKs and the JAK substates, STAT proteins 
(yellow circles) basally and in response to cytokines. Interestingly, kinase dead (KD) 
JAK1 S703I was capable of transactivating other JAK proteins and, thus, could 
potentiate aberrant cytokine signaling in cells independently of its kinase activity. The 
JAK1 S703I mutation triggered autoinflammation in the patient. The discovery that a 
pan-JAK inhibitor, and not just specific inhibition of JAK1, was required to reverse the 
biochemical changes intiated by expression of JAK1 S703I was key to identifying a 
treatment that reversed the clinical manifesations suffered by the patient.  
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